Aniling obtains European certification for diagnostic tests for chronic lymphocytic leukaemia, colorectal cancer and liquid biopsy

27 Jul 2022
www.biospace.com
First in Class
Llorenç Coll and Miguel A. Peinado, co-founders of Aniling, and Jaume Amat, strategic advisor and Board of Directors member. The GEUS-CLL, GEUS-CRC and GEUS-LB tests are the first to simultaneously and reliably analyse genetic and epigenetic biomarkers in a single clinical test. The CE certification opens the door for Aniling to market the three first-in-class tests in Europe. The biotech is in negotiations with international investors to close a €7 million Series A round. Badalona (Barcelona, Spain), 27 July 2022 - Aniling, a biotech company that develops solutions based on next-generation genomic and epigenomic sequencing (NGS) methods for precision oncology, has obtained CE certification for its first in vitro diagnostic (IVD) tests for chronic lymphocytic leukaemia, colorectal cancer and liquid biopsy. The CE mark authorises the company to market the tests throughout Europe. Aniling has successfully complied with the requirements established by the European Union to obtain the certification in Directive 98/79/EC and the new Regulation on in vitro diagnostic medical devices and has also implemented a Quality Management System according to the ISO 13485 standard. The GEUS-CLL, GEUS-CRC and GEUS-LB tests are based on the patented GEUS (Genomic and Epigenomic Unified Sequencing) technology which, for the first time, simultaneously and highly reliably analyses genetic and epigenetic biomarkers in a single clinical test. This advance means that the new GEUS-CLL and GEUS-CRC tests facilitate the diagnosis, prognosis and selection of the best treatment for each patient with chronic lymphocytic leukaemia and colon cancer, respectively. GEUS-LB is a liquid biopsy test that provides access to tumour DNA in a minimally invasive way and obtains genetic and epigenetic information that allows a faster and more accurate diagnosis. Cancer is the leading cause of death worldwide, according to the latest data from the World Health Organisation (WHO). The third most common cancer is colon cancer, with 1.8 million people diagnosed in 2020. Chronic lymphocytic leukaemia is the most common type of leukaemia in Western countries (between 20% and 40% of the total). "The CE marking on our tests is an important step to consolidate Aniling's market entry strategy and business project" says Dr Llorenç Coll, co-founder and CEO of Aniling. "We are very excited about this milestone that will allow us to bring precision medicine to millions of people" he adds. "Since 2014, we have focused on improving NGS methods to integrate molecular data into biologically relevant information that meets the high-quality standards required for clinical use. We have managed to improve data quality over other solutions on the market and develop an efficient test that replaces multiple tests and reduces turnaround times," explains Dr Miguel A Peinado, co-founder and Chief Scientific Officer of Aniling. Aniling has a scientific committee made up of renowned experts in clinical genetics and epigenetics such as Dr Susan Clark (Garvan Institute of Medical Research), Dr Elias Campo (Hospital Clinic-IDIBAPS), Dr Manel Esteller (Josep Carreras Leukaemia Research InstituteLeukaemia Research Institute) and Dr Ivo Gut (National Genomic Analysis Centre) and strategic advisors such as Jan Bonel, founder of Visiometrics; Jérôme Marzinski, expert in the medical device market and Jaume Amat, founder of Rob Surgical and Specipig and former president of CataloniaBio & HealthTech. The tests have been clinically validated in collaboration with leading healthcare institutions such as the Catalan Institute of Oncology (ICO), the Germans Trias i Pujol Research Institute (IGTP), the Hospital Clinic Barcelona and the Munich Leukemia LaboratoryLeukemia Laboratory (MLL). The company will focus in the coming months on negotiating a Series A round of €7 million to finance market entry, complete clinical validation and expand the product portfolio. …....... Aniling Aniling is a clinical-stage biotech company developing solutions based on next-generation genomic and epigenomic sequencing (NGS) methods for precision oncology. The company has patented GEUS (Genomic and Epigenomic Unified Sequencing) technology, which allows, for the first time, the simultaneous analysis of the genome and epigenome for clinical use and research. Currently, Aniling's pipeline consists of three in vitro diagnostic (IVD) tests for chronic lymphocytic leukaemia (GEUS-CLL), colorectal cancer (GEUS-CRC) and liquid biopsy (GEUS-LB) with CE-certification from the European Union. Aniling was founded in 2014 as a spin-off from the Institute of Predictive and Personalised Medicine of Cancer (IMPPC), currently part of the Germans Trias i Pujol Biomedical Research Institute (IGTP), and is based at the Can Ruti Campus in Badalona (Barcelona, Spain). The Can Ruti Campus is home to the Germans Trias i Pujol University Hospital, the Autonomous University of Barcelona and five biomedical research institutes (IGTP, Catalan Institute of Oncology, Josep Carreras Leukaemia Research InstituteLeukaemia Research Institute, IrsiCaixa and Guttmann Institute). The company is supported by private investors and sector entities such as EIT Health, the Spanish Ministry of Science and Innovation, the Centre for the Development of Industrial Technology (CDTI), ACCIÓ-Government of Catalonia, Biocat and CataloniaBio & HealthTech. So far, it has secured more than €5 million in funding. More information: aniling.com …....... Media contact: Gemma Escarré Comms info@gemmaescarre.com M +34 667 76 15 24 Follow us on LinkedIn
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.